Academic drug discovery: current status and prospects

Bibliography

• Kinch MS, Flath R. New drug discovery: extraordinary opportunities in an uncertain time. Drug Discov Today 2014. 10.1016/j.drudis.2014.12
   Google Scholar
• Mullard A. 2014 fda drug approvals. Nat Rev Drug Discov 2015;14(2):77–81
   PubMed Web of Science ®Google Scholar
• LaMattina JL. The impact of mergers on pharmaceutical R&D. Nature Reviews Drug Discovery 2011;10(8):559–60
   PubMed Web of Science ®Google Scholar
• Comanor WS, Scherer FM. Mergers and innovation in the pharmaceutical industry. J Health Econ 2013;32(1):106–13
   PubMed Web of Science ®Google Scholar
• Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve r&d productivity: The pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 2010;9(3):203–14
   PubMed Web of Science ®Google Scholar
• Morgan P, Van der Graaf PH, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase ii survival. Drug Discov Today 2012;17(9-10):419–24
   PubMed Web of Science ®Google Scholar
• Arrowsmith J. Phase II failures: 2008-2010. Nat Rev Drug Discov 2011;10(5):1
   Web of Science ®Google Scholar
• Rafols I, Hopkins MM, Hoekman J, et al. Big pharma, little science? A bibliometric perspective on big pharma’s r&d decline. Technol Forecast Soc Change 2014;81:22–38
   Web of Science ®Google Scholar
• Said M, Zerhouni E. The role of public-private partnerships in addressing the biomedical innovation challenge. Nature Reviews Drug Discovery 2014;13(11):789–90
   PubMed Web of Science ®Google Scholar
• Goldman M. The innovative medicines initiative: A european response to the innovation challenge. Clin Pharmacol Ther 2012;91(3):418–25
   PubMed Web of Science ®Google Scholar
• Chain E. Early years of the penicillin discovery. Trends Pharmacol Sci 1979;1(1):6–11
   Web of Science ®Google Scholar
• Nayler JHC. Early discoveries in the penicillin series. Trends Biochem Sci 1991;16(5):195–7
   PubMed Web of Science ®Google Scholar
• Nayler JHC. Structure-activity relationships in semi-synthetic penicillins. Proc R Soc Lond B Biol Sci 1971;179(1057):357–67
   PubMed Web of Science ®Google Scholar
• Frearson J, Wyatt P. Drug discovery in academia: The third way? Expert Opin Drug Discov 2010;5(10):909–19
   PubMed Web of Science ®Google Scholar
• Stevens AJ, Jensen JJ, Wyller K, et al. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364(6):535–41
   PubMed Web of Science ®Google Scholar
• Frye S, Crosby M, Edwards T, Juliano R. US academic drug discovery. Nat Rev Drug Discov 2011;10(6):409–10
   PubMed Web of Science ®Google Scholar
• Slusher BS, Conn PJ, Frye S, et al. Bringing together the academic drug discovery community. Nat Rev Drug Discov 2013;12(11):811–12
   PubMed Web of Science ®Google Scholar
• Academic drug discovery consortium (ad2c). 2015. Available from: http://addconsortium.Org/index.Php [Last accessed 2 June 2015]
   Google Scholar
• Society of laboratory automation and screening (slas). 2015. Available from: http://www.Slas.Org/resources/information/academic-screening-facilities/ [Last accessed 8 April 2015]
   Google Scholar
• Huryn DM, Resnick LO, Wipf P. Contributions of academic laboratories to the discovery and development of chemical biology tools. J Med Chem 2013;56(18):7161–76
   PubMed Web of Science ®Google Scholar
• Mullard A. European lead factory opens for business. Nat Rev Drug Discov 2013;12(3):173–5
   PubMed Web of Science ®Google Scholar
• Besnard J, Jones PS, Hopkins AL, Pannifer AD. The joint european compound library: Boosting precompetitive research. Drug discov today 2015;20(2):181–6
   PubMed Web of Science ®Google Scholar
• Orrling K. European lead factory status, personal communication. 2015
   Google Scholar
• Frank R. Eu-openscreen - a european infrastructure of open screening platforms for chemical biology. ACS Chem Biol 2014;9(4):853–4
   PubMed Web of Science ®Google Scholar
• Tralau-Stewart C, Low CMR, Marlin N. UK academic drug discovery. Nat Rev Drug Discov 2014;13(1):15–16
   PubMed Web of Science ®Google Scholar
• Schultz Kirkegaard H, Valentin F. Academic drug discovery centres: The economic and organisational sustainability of an emerging model. Drug discov today 2014;19(11):1699–710
   PubMed Web of Science ®Google Scholar
• Comley J. The current status of non-biopharma drug discovery. Drug Discovery World 2014;62–9
   Google Scholar
• Jorgensen WL. Challenges for academic drug discovery. Angew Chem Int Ed Engl 2012;51(47):11680–4
   PubMed Web of Science ®Google Scholar
• Huryn DM. Drug discovery in an academic setting: Playing to the strengths. ACS Med Chem Lett 2013;4(3):313–15
   PubMed Web of Science ®Google Scholar
• Dahlin JL, Inglese J, Walters MA. Mitigating risk in academic preclinical drug discovery. Nat Rev Drug Discov 2015;14:279–94
   PubMed Web of Science ®Google Scholar
• Baell JB. Observations on screening-based research and some concerning trends in the literature. Future Med Chem 2010;2(10):1529–46
   PubMed Web of Science ®Google Scholar
• Baell J, Walters MA. Chemical con artists foil drug discovery. Nature 2014;513(7519):481–3
   PubMed Web of Science ®Google Scholar
• Bell AS, Bradley J, Everett JR, et al. Plate-based diversity subset screening: An efficient paradigm for high throughput screening of a large screening file. Mol Divers 2013;17(2):319–35
   PubMed Web of Science ®Google Scholar
• Feng BY, Shoichet BK. Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. J Med Chem 2006;49(7):2151–4
   PubMed Web of Science ®Google Scholar
• Bakken GA, Bell AS, Boehm M, et al. Shaping a screening file for maximal. Lead discovery efficiency and effectiveness: Elimination of molecular redundancy. J Chem Inf Model 2012;52(11):2937–49
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53(7):2719–40
   PubMed Web of Science ®Google Scholar
• Whitty A. Growing pains in academic drug discovery. Future Med Chem 2011;3(7):797–801
   PubMed Web of Science ®Google Scholar
• Lane SJ, Eggleston DS, Brinded KA, et al. Defining and maintaining a high quality screening collection: The GSK experience. Drug Discov Today 2006;11(5-6):267–72
   PubMed Web of Science ®Google Scholar
• Tang H, Walsh SP, Yan Y, et al. Discovery of selective small molecule romk inhibitors as potential new mechanism diuretics. ACS Med Chem Lett 2012;3(5):367–72
   PubMed Web of Science ®Google Scholar
• Jacob NT, Lockner JW, Kravchenko VV, Janda KD. Pharmacophore reassignment for induction of the immunosurveillance cytokine trail. Angew Chem Int Ed Engl 2014;53(26):6628–31
   PubMed Web of Science ®Google Scholar
• Austin CP, Brady LS, Insel TR, Collins FS. NIH molecular libraries initiative. Science 2004;306(5699):1138–9
   PubMed Web of Science ®Google Scholar
• Molecular libraries program. 2007. Available from: http://www.Mli.Nih.Gov/mli/ [Last accessed 3 June 2015]
   Google Scholar
• Leinonen V, Rinne JO, Wong DF, et al. Diagnostic effectiveness of quantitative 18F flutemetamol pet imaging for detection of fibrillar amyloid beta using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. Acta neuropathol commun 2014;2:46
   Google Scholar
• Rpc1063 for rms. 2015. Available from: http://receptos.Com/clinical-pipeline/rpc1063-for-rms/ [Last accessed 3 June 2015]
   Google Scholar
• Oprea TI, Bologa CG, Boyer S, et al. A crowdsourcing evaluation of the NIH chemical probes. Nat Chem Biol 2009;5(7):441–7
   PubMed Web of Science ®Google Scholar
• Hopkins A, Lanfear J, Lipinski C, Beeley L. Chemical tools for indications discovery. Annu Rep Med Chem 2005;40:339–48
   Web of Science ®Google Scholar
• Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006;5(8):689–702
   PubMed Web of Science ®Google Scholar
• Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg 2011;8(3-4):61–9
   PubMedGoogle Scholar
• Nair P. Drug repurposing gets a boost as academic researchers join the search for novel uses of existing drugs. Proc Natl Acad Sci USA 2013;110(7):2430–2
   PubMed Web of Science ®Google Scholar
• Kaufman AC, Salazar SVH, Laura T, et al. Fyn inhibition rescues established memory and synapse loss in alzheimer mice. Ann Neurol 2015;77(6):953–71
   PubMed Web of Science ®Google Scholar
• Repurposed experimental cancer drug restores brain function in mouse models of alzheimer’s disease: NIH, NIH web site. 2015. Available from: http://www.nih.gov/news/health/mar2015/ncats-31.htm
   Google Scholar
• Bickle M. Systems drug discovery: A quantitative, objective approach for safer drug development. Expert Opin Drug Discov 2012;7(9):757–9
   PubMed Web of Science ®Google Scholar
• Lindon J, Nicholson J, Holmes E, Everett J. Metabonomics: Metabolic processes studied by NMR spectroscopy of biofluids. Concepts Magn Reson 2000;12(5):289–320
   Google Scholar
• Reily MD, Tymiak AA. Metabolomics in the pharmaceutical industry. Drug Discov Today: Technologies 2015
   PubMedGoogle Scholar
• Bento AP, Gaulton A, Hersey A, et al. The ChEMBL bioactivity database: An update. Nucleic Acids Res 2014;42(D1):D1083–90
   PubMed Web of Science ®Google Scholar
• Willighagen EL, Waagmeester A, Spjuth O, et al. The ChEMBL database as linked open data. J Cheminform 2013;5(1):23
   PubMedGoogle Scholar